<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39353631</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1488-2329</ISSN><JournalIssue CitedMedium="Internet"><Volume>196</Volume><Issue>32</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</Title><ISOAbbreviation>CMAJ</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2, Tdap, and influenza vaccination during pregnancy from 2019 to 2022 in Ontario, Canada: a population-based retrospective cohort study.</ArticleTitle><Pagination><StartPage>E1100</StartPage><EndPage>E1113</EndPage><MedlinePgn>E1100-E1113</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1503/cmaj.231522</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hesitancy about vaccination during pregnancy posed challenges to SARS-CoV-2 vaccination efforts. We aimed to examine rates of SARS-CoV-2 vaccination among Ontario residents who gave birth in early 2022, and to compare rates of SARS-CoV-2 vaccine uptake with rates of tetanus, diphtheria, and pertussis (Tdap) and influenza vaccination during pregnancy in 2019, 2021, and 2022.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a population-based retrospective cohort study to describe vaccination rates among pregnant and comparable nonpregnant populations in Ontario using linked administrative data. Provincially insured females who had a live, in-hospital birth from Jan. 1 to Mar. 31 in 2019, 2021, or 2022 were our primary cohort. Using log-binomial regression, we tested associations between SARS-CoV-2 (2022) and Tdap and influenza (2019, 2021, 2022) vaccination status, with birth group and covariates. We compared SARS-CoV-2 vaccination status with the status of a matched cohort of nonpregnant females and conducted subgroup analyses by age and prenatal clinician type.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among birthing people, 78.7% received their first SARS-CoV-2 vaccine dose and 74.2% received a second dose. The rate was significantly higher among nonpregnant comparators (dose 1: relative risk [RR] 0.94, 95% confidence interval [CI] 0.93-0.94; dose 2: RR 0.91, 95% CI 0.90-0.91). However, the rate of SARS-CoV-2 vaccination uptake among birthing people was higher than uptake of Tdap or influenza vaccination. Tetanus, diphtheria, and pertussis vaccination increased over time from 22.2% in 2019 to 32.6% in 2022, and influenza vaccination rose to 35.3% in 2021 but returned to prepandemic levels in 2022 (27.7%). Vaccination rates were lower among pregnant people who were young, multiparous, or residents of rural or economically deprived areas for all 3 vaccines.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Rates of SARS-CoV-2 vaccination were lower among pregnant people than among nonpregnant comparators but were higher than rates of routinely recommended Tdap and influenza vaccinations. Pandemic urgency may have overcome a great deal of hesitancy about vaccinating against SARS-CoV-2 during pregnancy in 2022, but uptake of routinely recommended vaccines in pregnancy remains a challenge.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Clinicaltrials.gov, no. NCT05663762.</AbstractText><CopyrightInformation>© 2024 CMA Impact Inc. or its licensors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Greyson</LastName><ForeName>Devon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Population and Public Health (Greyson, Mniszak), University of British Columbia; Vaccine Evaluation Center (Greyson), British Columbia Children's Hospital Research Institute, Vancouver, BC; Department of Family Medicine (Correia, Howard, Davis, Molinaro, Vanstone), and Department of Obstetrics and Gynecology (Darling), and ICES McMaster (Darling, Jones), and Department of Health Research Methods, Evidence and Impact (Darling, Jones), McMaster University, Hamilton, Ont.; Institute for Health Sciences Education (Kirkwood, Molinaro), McGill University, Montréal, Que.; Centre for Health Economics and Policy Analysis (Vanstone), McMaster University, Hamilton, Ont. devon.greyson@ubc.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Correia</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Population and Public Health (Greyson, Mniszak), University of British Columbia; Vaccine Evaluation Center (Greyson), British Columbia Children's Hospital Research Institute, Vancouver, BC; Department of Family Medicine (Correia, Howard, Davis, Molinaro, Vanstone), and Department of Obstetrics and Gynecology (Darling), and ICES McMaster (Darling, Jones), and Department of Health Research Methods, Evidence and Impact (Darling, Jones), McMaster University, Hamilton, Ont.; Institute for Health Sciences Education (Kirkwood, Molinaro), McGill University, Montréal, Que.; Centre for Health Economics and Policy Analysis (Vanstone), McMaster University, Hamilton, Ont.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Population and Public Health (Greyson, Mniszak), University of British Columbia; Vaccine Evaluation Center (Greyson), British Columbia Children's Hospital Research Institute, Vancouver, BC; Department of Family Medicine (Correia, Howard, Davis, Molinaro, Vanstone), and Department of Obstetrics and Gynecology (Darling), and ICES McMaster (Darling, Jones), and Department of Health Research Methods, Evidence and Impact (Darling, Jones), McMaster University, Hamilton, Ont.; Institute for Health Sciences Education (Kirkwood, Molinaro), McGill University, Montréal, Que.; Centre for Health Economics and Policy Analysis (Vanstone), McMaster University, Hamilton, Ont.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darling</LastName><ForeName>Elizabeth K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>School of Population and Public Health (Greyson, Mniszak), University of British Columbia; Vaccine Evaluation Center (Greyson), British Columbia Children's Hospital Research Institute, Vancouver, BC; Department of Family Medicine (Correia, Howard, Davis, Molinaro, Vanstone), and Department of Obstetrics and Gynecology (Darling), and ICES McMaster (Darling, Jones), and Department of Health Research Methods, Evidence and Impact (Darling, Jones), McMaster University, Hamilton, Ont.; Institute for Health Sciences Education (Kirkwood, Molinaro), McGill University, Montréal, Que.; Centre for Health Economics and Policy Analysis (Vanstone), McMaster University, Hamilton, Ont.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkwood</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Population and Public Health (Greyson, Mniszak), University of British Columbia; Vaccine Evaluation Center (Greyson), British Columbia Children's Hospital Research Institute, Vancouver, BC; Department of Family Medicine (Correia, Howard, Davis, Molinaro, Vanstone), and Department of Obstetrics and Gynecology (Darling), and ICES McMaster (Darling, Jones), and Department of Health Research Methods, Evidence and Impact (Darling, Jones), McMaster University, Hamilton, Ont.; Institute for Health Sciences Education (Kirkwood, Molinaro), McGill University, Montréal, Que.; Centre for Health Economics and Policy Analysis (Vanstone), McMaster University, Hamilton, Ont.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Amie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Population and Public Health (Greyson, Mniszak), University of British Columbia; Vaccine Evaluation Center (Greyson), British Columbia Children's Hospital Research Institute, Vancouver, BC; Department of Family Medicine (Correia, Howard, Davis, Molinaro, Vanstone), and Department of Obstetrics and Gynecology (Darling), and ICES McMaster (Darling, Jones), and Department of Health Research Methods, Evidence and Impact (Darling, Jones), McMaster University, Hamilton, Ont.; Institute for Health Sciences Education (Kirkwood, Molinaro), McGill University, Montréal, Que.; Centre for Health Economics and Policy Analysis (Vanstone), McMaster University, Hamilton, Ont.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mniszak</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Population and Public Health (Greyson, Mniszak), University of British Columbia; Vaccine Evaluation Center (Greyson), British Columbia Children's Hospital Research Institute, Vancouver, BC; Department of Family Medicine (Correia, Howard, Davis, Molinaro, Vanstone), and Department of Obstetrics and Gynecology (Darling), and ICES McMaster (Darling, Jones), and Department of Health Research Methods, Evidence and Impact (Darling, Jones), McMaster University, Hamilton, Ont.; Institute for Health Sciences Education (Kirkwood, Molinaro), McGill University, Montréal, Que.; Centre for Health Economics and Policy Analysis (Vanstone), McMaster University, Hamilton, Ont.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Population and Public Health (Greyson, Mniszak), University of British Columbia; Vaccine Evaluation Center (Greyson), British Columbia Children's Hospital Research Institute, Vancouver, BC; Department of Family Medicine (Correia, Howard, Davis, Molinaro, Vanstone), and Department of Obstetrics and Gynecology (Darling), and ICES McMaster (Darling, Jones), and Department of Health Research Methods, Evidence and Impact (Darling, Jones), McMaster University, Hamilton, Ont.; Institute for Health Sciences Education (Kirkwood, Molinaro), McGill University, Montréal, Que.; Centre for Health Economics and Policy Analysis (Vanstone), McMaster University, Hamilton, Ont.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinaro</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Population and Public Health (Greyson, Mniszak), University of British Columbia; Vaccine Evaluation Center (Greyson), British Columbia Children's Hospital Research Institute, Vancouver, BC; Department of Family Medicine (Correia, Howard, Davis, Molinaro, Vanstone), and Department of Obstetrics and Gynecology (Darling), and ICES McMaster (Darling, Jones), and Department of Health Research Methods, Evidence and Impact (Darling, Jones), McMaster University, Hamilton, Ont.; Institute for Health Sciences Education (Kirkwood, Molinaro), McGill University, Montréal, Que.; Centre for Health Economics and Policy Analysis (Vanstone), McMaster University, Hamilton, Ont.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanstone</LastName><ForeName>Meredith</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Population and Public Health (Greyson, Mniszak), University of British Columbia; Vaccine Evaluation Center (Greyson), British Columbia Children's Hospital Research Institute, Vancouver, BC; Department of Family Medicine (Correia, Howard, Davis, Molinaro, Vanstone), and Department of Obstetrics and Gynecology (Darling), and ICES McMaster (Darling, Jones), and Department of Health Research Methods, Evidence and Impact (Darling, Jones), McMaster University, Hamilton, Ont.; Institute for Health Sciences Education (Kirkwood, Molinaro), McGill University, Montréal, Que.; Centre for Health Economics and Policy Analysis (Vanstone), McMaster University, Hamilton, Ont.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05663762</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>CMAJ</MedlineTA><NlmUniqueID>9711805</NlmUniqueID><ISSNLinking>0820-3946</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022681">Diphtheria-Tetanus-acellular Pertussis Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022681" MajorTopicYN="Y">Diphtheria-Tetanus-acellular Pertussis Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011251" MajorTopicYN="N">Pregnancy Complications, Infectious</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests:: Devon Greyson reports support for other research from the Canadian Institutes of Health Research (CIHR), British Columbia Immunization Committee, Canadian Immunization Research Network, BC Children’s Hospital Research Canucks for Kids Fund, University of British Columbia (UBC) Hampton Fund, UBC Faculty of Medicine, and Social Sciences and Humanities Research Council. Dr. Greyson also reports honoraria from the University of Sydney and University of Oulu, and unpaid membership with the Association for Information Science and Technology Special Interest Group on Health Information Executive Committee. Meredith Vanstone reports CIHR salary support from Canada Research Chairs program, Banting Postdoctoral Fellowships, Michael Smith Health Research BC Scholar Award, and CIHR/Public Health Agency of Canada (PHAC) Applied Public Health Chair.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>22</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39353631</ArticleId><ArticleId IdType="pmc">PMC11444691</ArticleId><ArticleId IdType="doi">10.1503/cmaj.231522</ArticleId><ArticleId IdType="pii">196/32/E1100</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Woodworth KR, O’Malley Olsen E, Neelam V, et al. CDC COVID-19 Response Pregnancy and Infant Linked Outcomes Team; COVID-19 Pregnancy and Infant Linked Outcomes Team (PILOT). Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy: SET-NET, 16 Jurisdictions, March 29–October 14, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1635–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7643898</ArticleId><ArticleId IdType="pubmed">33151917</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano LD, Ellington S, Strid P, et al. CDC COVID-19 Response Pregnancy and Infant Linked Outcomes Team. Update: Characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status: United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1641–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7643892</ArticleId><ArticleId IdType="pubmed">33151921</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei SQ, Bilodeau-Bertrand M, Liu S, et al. . The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ 2021;193: E540–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084555</ArticleId><ArticleId IdType="pubmed">33741725</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar J, Ariff S, Gunier RB, et al. . Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTER-COVID multinational cohort study. JAMA Pediatr 2021;175:817–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8063132</ArticleId><ArticleId IdType="pubmed">33885740</ArticleId></ArticleIdList></Reference><Reference><Citation>Allotey J, Stallings E, Bonet M, et al. PregCOV-19 Living Systematic Review Consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020;370:m3320. doi:10.1136/bmj.m3320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3320</ArticleId><ArticleId IdType="pmc">PMC7459193</ArticleId><ArticleId IdType="pubmed">32873575</ArticleId></ArticleIdList></Reference><Reference><Citation>Mark EG, McAleese S, Golden WC, et al. . Coronavirus disease 2019 in pregnancy and outcomes among pregnant women and neonates: a literature review. Pediatr Infect Dis J 2021;40:473–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8048372</ArticleId><ArticleId IdType="pubmed">33847297</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Mascio D, Khalil A, Saccone G, et al. . Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2020;2:100107. doi:10.1016/j.ajogmf.2020.100107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajogmf.2020.100107</ArticleId><ArticleId IdType="pmc">PMC7104131</ArticleId><ArticleId IdType="pubmed">32292902</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt JS, Fell DB. SARS-CoV-2 infection in pregnancy: lessons learned from the first pandemic wave. Paediatr Perinat Epidemiol 2021;35:34–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013326</ArticleId><ArticleId IdType="pubmed">33496991</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor MM, Kobeissi L, Kim C, et al. . Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action. Lancet Glob Health 2021;9: e366–71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832459</ArticleId><ArticleId IdType="pubmed">33340453</ArticleId></ArticleIdList></Reference><Reference><Citation>Kons KM, Wood ML, Peck LC, et al. . Exclusion of reproductive-aged women in COVID-19 vaccination and clinical trials. Womens Health Issues 2022;32:557–63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9197956</ArticleId><ArticleId IdType="pubmed">36075817</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloum M, Paviotti A, Bastiaens H, et al. . The inclusion of pregnant women in vaccine clinical trials: an overview of late-stage clinical trials’ records between 2018 and 2023. Vaccine 2023;41:7076–83.</Citation><ArticleIdList><ArticleId IdType="pubmed">37903681</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan AK, Fell DB, Wise LA, et al. . Challenges and opportunities for the epidemiological evaluation of the effects of COVID-19 vaccination on reproduction and pregnancy. Vaccine 2023;41:5931–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">37659894</ArticleId></ArticleIdList></Reference><Reference><Citation>Archived 9: National Advisory Committee on Immunization — Summary of updated vaccine statement of May 3, 2021. Ottawa: Public Health Agency of Canada; modified 2021 Dec. 23. Available: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/summary-updated-statement-may-3-2021.html (accessed 2023 July 10).</Citation></Reference><Reference><Citation>Poliquin V, Castillo E, Boucoiran I, et al. . SOGC statement on COVID-19 vaccination in pregnancy. Ottawa: The Society of Obstetricians and Gynaecologists of Canada (SOGC); 2020, revised 2022 Mar. 14:1–12. Available: https://sogc.org/common/Uploaded%20files/Latest%20News/SOGC_Statement_COVID-19_Vaccination_in_Pregnancy.pdf (accessed 2023 July 10).</Citation></Reference><Reference><Citation>Report #5: COVID-19 vaccination during pregnancy in Ontario — December 14, 2020 to May 31, 2022. Ottawa: BORN Ontario. Available: https://www.bornontario.ca/en/whats-happening/resources/Documents/COVID-19-Vaccination-during-pregnancy-in-Ontario_Report_Dec2020-May2022.pdf (accessed 2023 July 10).</Citation></Reference><Reference><Citation>Magnus MC, Gjessing HK, Eide HN, et al. . COVID-19 vaccination during pregnancy and first-trimester miscarriage. N Engl J Med 2021;385:2008–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8552533</ArticleId><ArticleId IdType="pubmed">34670062</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, D’Souza R, Kharrat A, et al. . COVID-19 pandemic and population-level pregnancy and neonatal outcomes: a living systematic review and meta-analysis. Acta Obstet Gynecol Scand 2021;100:1756–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8222877</ArticleId><ArticleId IdType="pubmed">34096034</ArticleId></ArticleIdList></Reference><Reference><Citation>Fell DB, Dhinsa T, Alton GD, et al. . Association of COVID-19 vaccination in pregnancy with adverse peripartum outcomes. JAMA 2022;327:1478–87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8949767</ArticleId><ArticleId IdType="pubmed">35323842</ArticleId></ArticleIdList></Reference><Reference><Citation>Fell D, Dimanlig-Cruz S, Török E, et al. . Risk of preterm birth, small-for-gestational-age at birth, and stillbirth after receiving a booster dose of COVID-19 vaccine during pregnancy. J Obstet Gynaecol Can 2023;45:353.</Citation></Reference><Reference><Citation>Jorgensen SCJ, Drover SSM, Fell DB, et al. . Newborn and early infant outcomes following maternal COVID-19 vaccination during pregnancy. JAMA Pediatr 2023; 177:1314–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10594175</ArticleId><ArticleId IdType="pubmed">37870875</ArticleId></ArticleIdList></Reference><Reference><Citation>Skjefte M, Ngirbabul M, Akeju O, et al. . COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries. Eur J Epidemiol 2021;36:197–211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7920402</ArticleId><ArticleId IdType="pubmed">33649879</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramlawi S, Muldoon KA, Dunn SI, et al. . Worries, beliefs and factors influencing perinatal COVID-19 vaccination: a cross-sectional survey of preconception, pregnant and lactating individuals. BMC Public Health 2022;22:2418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9780097</ArticleId><ArticleId IdType="pubmed">36550543</ArticleId></ArticleIdList></Reference><Reference><Citation>Misinformation about COVID-19 vaccines and pregnancy is widespread, including among women who are pregnant or planning to get pregnant [news release]. San Francisco: Kaiser Family Foundation; 2022. 
May
27. Available: https://www.kff.org/coronavirus-covid-19/press-release/misinformation-about-covid-19-vaccines-and-pregnancy-is-widespread-including-among-women-who-are-pregnant-or-planning-to-get-pregnant/ (accessed 2023 July 10).</Citation></Reference><Reference><Citation>Eldeib D. How misinformation about COVID vaccines and pregnancy took root early on and why it won’t go away. New York: ProPublica; 2022. Available: https://www.propublica.org/article/covid-misinformation-pregnancy-vaccine-testing (accessed 2023 July 10).</Citation></Reference><Reference><Citation>Schraer R. Covid: pregnant women targeted with false vaccine claims. BBC News
2022. 
Aug.
31. Available: https://www.bbc.com/news/health-62739554 (accessed 2023 July 10).</Citation></Reference><Reference><Citation>Hsu AL, Johnson T, Phillips L, et al. . Sources of vaccine hesitancy: pregnancy, infertility, minority concerns, and general skepticism. Open Forum Infect Dis 2022; 9:ofab433. doi: 10.1093/ofid/ofab433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab433</ArticleId><ArticleId IdType="pmc">PMC8385996</ArticleId><ArticleId IdType="pubmed">35141344</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacs-Thomas B. There’s no evidence COVID-19 vaccines hurt fertility. Here’s what’s fueling the myth. PBS News
2021. 
Sept.
16. Available: https://www.pbs.org/newshour/health/how-anti-vaccine-scare-tactics-exploit-our-fertility-anxieties (accessed 2023 July 10).</Citation></Reference><Reference><Citation>Fell DB, Török E, Sprague AE, et al. . Temporal trends and determinants of COVID-19 vaccine coverage and series initiation during pregnancy in Ontario, Canada, December 2020 to December 2021: a population-based retrospective cohort study. Vaccine 2023;41:1716–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9894778</ArticleId><ArticleId IdType="pubmed">36759282</ArticleId></ArticleIdList></Reference><Reference><Citation>Török E, Dhinsa T, Dimanlig-Cruz S, et al. . Temporal trends and determinants of COVID-19 vaccine series initiation after recent pregnancy. Hum Vaccin Immunother 2023;19:2215150. doi:10.1080/21645515.2023.2215150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2215150</ArticleId><ArticleId IdType="pmc">PMC10305504</ArticleId><ArticleId IdType="pubmed">37249316</ArticleId></ArticleIdList></Reference><Reference><Citation>Poliquin V, Greyson D, Castillo E. A systematic review of barriers to vaccination during pregnancy in the Canadian context. J Obstet Gynaecol Can 2019;41: 1344–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">30361161</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan AK, Mak DB, Hauck YL, et al. . Trends in seasonal influenza vaccine uptake during pregnancy in Western Australia: implications for midwives. Women Birth 2016;29:423–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26879102</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary BJ, Rice Ú, Eogan M, et al. . 2009 A/H1N1 influenza vaccination in pregnancy: uptake and pregnancy outcomes: a historical cohort study. Eur J Obstet Gynecol Reprod Biol 2014;178:163–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24793932</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber A, Muscoplat MH, Fedorowicz A. Coverage with tetanus, diphtheria, and acellular pertussis vaccine and influenza vaccine among pregnant women: Minnesota, March 2013–December 2014. MMWR Morb Mortal Wkly Rep 2017; 66:56–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657652</ArticleId><ArticleId IdType="pubmed">28103212</ArticleId></ArticleIdList></Reference><Reference><Citation>Halperin BA, MacKinnon-Cameron D, McNeil S, et al. . Maintaining the momentum: key factors influencing acceptance of influenza vaccination among pregnant women following the H1N1 pandemic. Hum Vaccin Immunother 2014; 10:3629–41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4514062</ArticleId><ArticleId IdType="pubmed">25668670</ArticleId></ArticleIdList></Reference><Reference><Citation>Results of the survey on vaccination during pregnancy 2021. Ottawa: Public Health Agency of Canada; modified 2022 Dec. 13. Available: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/survey-vaccination-during-pregnancy-2021.html (accessed 2023 July 10).</Citation></Reference><Reference><Citation>Brophy J, Baclic O, Tunis M; National Advisory Committee on Immunization (NACI). Summary of the NACI update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine. Can Commun Dis Rep
2018;44:91–4
Available: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2018-44/issue-3-4-march-1-2018/article-5-update-immunization-pregnancy-vaccine-2018.html (accessed 2023 Apr. 14).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6449114</ArticleId><ArticleId IdType="pubmed">31007617</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhraei R, Fung SG, Petrcich W, et al. . Trends and characteristics of Tdap vaccination during pregnancy in Ontario, Canada: a retrospective cohort study. CMAJ Open 2022;10:E1017–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9744266</ArticleId><ArticleId IdType="pubmed">36735222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sell H, Assi A, Driedger SM, et al. . Continuity of routine immunization programs in Canada during the COVID-19 pandemic. Vaccine 2021;39:5532–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8439618</ArticleId><ArticleId IdType="pubmed">34426028</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 pandemic fuels largest continued backslide in vaccinations in three decades [news release]. Geneva: World Health Organization; 2022. 
July
15, 2022. Available: https://www.who.int/news/item/15-07-2022-covid-19-pandemic-fuels-largest-continued-backslide-in-vaccinations-in-three-decades (accessed 2023 July 10).</Citation></Reference><Reference><Citation>Updated guidance on influenza vaccination during pregnancy. Public Health Agency of Canada; modified 2023 Dec. 18:1–81. Available: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-updated-guidance-influenza-vaccination-during-pregnancy.html (accessed 2024 May 25).</Citation></Reference><Reference><Citation>Sander B, Kwong JC, Bauch CT, et al. . Economic appraisal of Ontario’s Universal Influenza Immunization Program: a cost–utility analysis. PLoS Med 2010;7:e1000256. doi:10.1371/journal.pmed.1000256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000256</ArticleId><ArticleId IdType="pmc">PMC2850382</ArticleId><ArticleId IdType="pubmed">20386727</ArticleId></ArticleIdList></Reference><Reference><Citation>Mijović H, Greyson D, Gemmell E, et al. . Perinatal health care providers’ approaches to recommending and providing pertussis vaccination in pregnancy: a qualitative study. CMAJ Open 2020;8:E377–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7239636</ArticleId><ArticleId IdType="pubmed">32414884</ArticleId></ArticleIdList></Reference><Reference><Citation>Tdap (tetanus, diphtheria, pertussis) Vaccine Program. Toronto: Ministry of Health and Long-Term Care:1-5. Available: https://www.health.gov.on.ca/en/public/programs/immunization/docs/tdap_fs_en.pdf (accessed 2023 Aug. 4).</Citation></Reference><Reference><Citation>Vanstone M, Correia R, Howard M, et al. . How do perceptions of COVID-19 risk impact pregnancy-related health decisions? A convergent parallel mixed-methods study protocol. PLoS One 2023;18:e0288952. doi:10.1371/journal.pone.0288952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0288952</ArticleId><ArticleId IdType="pmc">PMC10414672</ArticleId><ArticleId IdType="pubmed">37561748</ArticleId></ArticleIdList></Reference><Reference><Citation>Benchimol EI, Smeeth L, Guttmann A, et al. RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med 2015;12:e1001885. doi:10.1371/journal.pmed.1001885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001885</ArticleId><ArticleId IdType="pmc">PMC4595218</ArticleId><ArticleId IdType="pubmed">26440803</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistics Canada, Canadian Vital Statistics: Birth database (CVSB). Ottawa: Statistics Canada; 2022. 
Sept.
27. Available: https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&amp;Id=1456141 (accessed 2024 Mar. 8).</Citation></Reference><Reference><Citation>The Canadian Index of Multiple Deprivation: user guide. Ottawa: Statistics Canada; 2019. Available: https://publications.gc.ca/site/eng/9.871994/publication.html (accessed 2023 Aug. 14).</Citation></Reference><Reference><Citation>Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399–424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Flannery DD, Gouma S, Dhudasia MB, et al. . Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios. JAMA Pediatr 2021;175:594–600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7846944</ArticleId><ArticleId IdType="pubmed">33512440</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen SCJ, Burry L, Tabbara N. Role of maternal COVID-19 vaccination in providing immunological protection to the newborn. Pharmacotherapy 2022; 42: 58–70.</Citation><ArticleIdList><ArticleId IdType="pubmed">34816467</ArticleId></ArticleIdList></Reference><Reference><Citation>Committee on Ethics. ACOG Committee Opinion No. 646: Ethical considerations for including women as research participants. Obstet Gynecol 2015; 126: e100–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26488521</ArticleId></ArticleIdList></Reference><Reference><Citation>Summary of NACI statement of May 17, 2024: statement on the prevention of respiratory syncytial virus disease in infants. Ottawa: Public Health Agency of Canada; updated 2024 June 21:1–6. Available: https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-statement-prevention-respiratory-syncytial-virus-disease-infants.html (accessed 2024 Aug. 3).</Citation></Reference><Reference><Citation>Madhi SA, Anderson AS, Absalon J, et al. . Potential for maternally administered vaccine for infant group B streptococcus. N Engl J Med 2023;389:215–27.</Citation><ArticleIdList><ArticleId IdType="pubmed">37467497</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong JC, Manuel DG. Using OHIP physician billing claims to ascertain individual influenza vaccination status. Vaccine 2007;25:1270–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079057</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz KL, Jembere N, Campitelli MA, et al. . Using physician billing claims from the Ontario Health Insurance Plan to determine individual influenza vaccination status: an updated validation study. CMAJ Open 2016;4:E463–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047797</ArticleId><ArticleId IdType="pubmed">27730110</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobbs JL, Paul LA, Buchan SA, et al. . Methodological changes implemented over time to support accurate and timely COVID-19 vaccine coverage estimates: Ontario, Canada. Vaccine 2023;41:3328–36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10080273</ArticleId><ArticleId IdType="pubmed">37087395</ArticleId></ArticleIdList></Reference><Reference><Citation>Pampalon R, Hamel D, Gamache P, et al. . A deprivation index for health planning in Canada. Chronic Dis Can 2009;29:178–91.</Citation><ArticleIdList><ArticleId IdType="pubmed">19804682</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>